Schisandrin (10-100 μM; pretreated for 2 h) inhibits LPS-stimulated NO production, iNOS protein and mRNA expression in a dose-dependent manner in RAW 264.7 cells.
Schisandrin (25-100 μM; pretreated for 2 h) inhibits prostaglandin E2 production, COX-2 protein and mRNA expression in LPS-stimulated RAW 264.7 macrophages.
Schisandrin inhibits the SK-HEP-1, SNU-638, and T47D cells proliferation, with IC50s of 42.0, 53.1, and 40.0 μM, respectively.
Schisandrin (10-60 μM; 48 h) enhances Doxorubicin -induced apoptosis and selectively reverses MCF-7/DOX resistance.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line: |
RAW 264.7 macrophages |
Concentration: |
12.5, 25, 50, 100 μM |
Incubation Time: |
Pretreated for 2 h and then incubated with LPS (1 μg/mL) for 18 h |
Result: |
Markedly decreased iNOS protein expression a dose-dependent manner.
Significantly inhibited COX-2 protein expression.
|